NVIV will maybe cross $3... the float on the stock is too low and with such poor liquidity their can't be that much upside. Just not enough supply of stock and shares that will drive the stock up that much... we can see $7 after trials commence from an potential acquirer (JNJ). NVIV needs to get on a bigger exchange and increase float and liquidity to take some power from MM's and allow the stock to move as it should.
Everyone is focusing in on the scaffold trial and what its effect will be on pps. However I think a greater stimulus to the pps will come from the hydrogel technology they are developing (and has also been submitted to the FDA)--Where as the scaffold trial will be considered more of an "orphan" drug/device (~potential 4000 patients/year who could benefit) the hydrogel work will impact a far greater patient population (sciatica, chronic nerve root pain, prostate cancer bone metastasis pain etc). This is where I believe the true stock value will increase
In my limited experience with these developing biotechs, the pps tends to increase much slower than the early investor base (us) tends to hope it will. I try to keep my expectations comparatively "low" to limit any disappointment I may have if my price target isn't reached. My conservative (but IMO realistic) estimates are $2.75-$3.00 after HUD status is approved, and $3.50-$4.00 after trial start is approved.
If/when NVIV is able to provide proof of concept in human trials, hopefully by the end of this year, then that's when I expect the fireworks to start. Of course, the results will largely determine where it goes. Getting feeling back in their legs is no where near getting patients up and walking again.
One more thing I'll add here, even with my conservative estimates, $2.75 is still a 50% return on top of the $1.80 PPS that we're at now. And $3.50 is yet another 20%+. Pretty clear the delays are impacting the share price, but where else can an investor get 100%+ return in a year? There certainly are other opportunities, but the potential in this company is hard to ignore, regardless of if you're on the buy or the sell side.